The reported statements, read against the company's own industry.
Financials view
Market Capitalization
610.84MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Revenue (TTM)
323.93MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Profit Margin
-26.05%
vs Diagnostics & Research peers
Updated Sep 27, 2026
Beta
0.9280x
vs all stocks
Updated Sep 27, 2026
52-Week Change
-0.45%
vs all stocks
Updated Sep 27, 2026
Market Capitalization
610.84MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Enterprise Value
357.78MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Forward P/E
-16.09x
vs Diagnostics & Research peers
Updated Sep 27, 2026
Price to Sales (TTM)
1.89x
vs Diagnostics & Research peers
Updated Sep 27, 2026
Price to Book (MRQ)
0.6098x
vs Diagnostics & Research peers
Updated Sep 27, 2026
Enterprise to Revenue
1.10x
vs Diagnostics & Research peers
Updated Sep 27, 2026
Enterprise to EBITDA
-4.00x
vs Diagnostics & Research peers
Updated Sep 27, 2026
Gross Margin
30.07%
vs Diagnostics & Research peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 35.58%.Updated Sep 27, 2026
Profit Margin
-26.05%
vs Diagnostics & Research peers
Updated Sep 27, 2026
Operating Margin
-39.35%
vs Diagnostics & Research peers
Updated Sep 27, 2026
Return on Assets (TTM)
-6.30%
vs Diagnostics & Research peers
Updated Sep 27, 2026
Return on Equity (TTM)
-8.11%
vs Diagnostics & Research peers
Updated Sep 27, 2026
Revenue (TTM)
323.93MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Revenue per Share (TTM)
10.74USDUpdated Sep 27, 2026
Quarterly Revenue Growth
4.40%
vs Diagnostics & Research peers
Updated Sep 27, 2026
Gross Profit (TTM)
115.26MUSD
vs all stocks (USD)
Updated Sep 27, 2026
EBITDA (TTM)
-89.46MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Net Income (TTM)
-84.38MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Quarterly Earnings Growth (YoY)
4.38%
vs Diagnostics & Research peers
Updated Sep 27, 2026
Operating Cash Flow (TTM)
-83.70MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Levered Free Cash Flow (TTM)
-90.90MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Sep 27, 2026
Payout Ratio
0.00%
vs Diagnostics & Research peers
Updated Sep 27, 2026
Minority Interest (Equity)
-5.27MUSDFY2025 · Dec 31, 2025
Revenue
322.67MUSDFY2025 · Dec 31, 2025
Cost of Goods Sold
191.80MUSDFY2025 · Dec 31, 2025
Gross Profit
130.88MUSDFY2025 · Dec 31, 2025
Operating Income
-91.10MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-70.03MUSDFY2025 · Dec 31, 2025
Income Tax Expense
-8.39MUSDFY2025 · Dec 31, 2025
Net Income
-61.63MUSDFY2025 · Dec 31, 2025
EBIT
-69.95MUSDFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-35.90MUSDFY2025 · Dec 31, 2025
Research & Development
53.91MUSDFY2025 · Dec 31, 2025
Selling, General & Administrative
160.03MUSDFY2025 · Dec 31, 2025
Non-operating Interest Income
30.92MUSDFY2025 · Dec 31, 2025
Non-operating Interest Expense
75.00KUSDFY2025 · Dec 31, 2025
EPS (Basic)
-1.97USDFY2025 · Dec 31, 2025
EPS (Diluted)
-1.97USDFY2025 · Dec 31, 2025
Basic Shares Outstanding
30.78MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
30.78MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-61.63MUSDFY2025 · Dec 31, 2025
Minority Interests (P&L)
1.12MUSDFY2025 · Dec 31, 2025
Operating Cash Flow
-122.95MUSDFY2025 · Dec 31, 2025
Free Cash Flow
-145.52MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
50.33MUSDFY2025 · Dec 31, 2025
Income Tax Paid
96.44MUSDFY2025 · Dec 31, 2025
Interest Paid
52.00KUSDFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-61.63MUSDFY2025 · Dec 31, 2025
Depreciation & Amortization
24.12MUSDFY2025 · Dec 31, 2025
Deferred Taxes (CF)
-278.00KUSDFY2025 · Dec 31, 2025
Stock-based Compensation
39.58MUSDFY2025 · Dec 31, 2025
Other Non-cash Items
1.79MUSDFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-23.25MUSDFY2025 · Dec 31, 2025
Change in Accounts Payable (CF)
550.00KUSDFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-103.84MUSDFY2025 · Dec 31, 2025
Capital Expenditures
-22.57MUSDFY2025 · Dec 31, 2025
Net Acquisitions
3.77MUSDFY2025 · Dec 31, 2025
Purchase of Investments
-80.84MUSDFY2025 · Dec 31, 2025
Sale of Investments
211.01MUSDFY2025 · Dec 31, 2025
Net Investing Cash Flow
111.37MUSDFY2025 · Dec 31, 2025
Long-term Debt Payments
-870.00KUSDFY2025 · Dec 31, 2025
Net Short-term Debt Issuance
-471.00KUSDFY2025 · Dec 31, 2025
Common Stock Repurchase
-13.92MUSDFY2025 · Dec 31, 2025
Net Financing Cash Flow
-15.26MUSDFY2025 · Dec 31, 2025
Shares Outstanding
27.52MSharesUpdated Sep 27, 2026
Float Shares
16.69MSharesUpdated Sep 27, 2026
Shares Short
2.32MSharesUpdated Sep 27, 2026
Short Ratio
7.96days
vs all stocks
Updated Sep 27, 2026
Short % of Shares Outstanding
13.53%
vs all stocks
Provider-reported. Shares Short ÷ Shares Outstanding on this page gives 8.42%.Updated Sep 27, 2026
% Held by Insiders
37.75%
vs all stocks
Updated Sep 27, 2026
% Held by Institutions
58.56%
vs all stocks
Updated Sep 27, 2026
Total Cash (MRQ)
257.03MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Total Cash per Share (MRQ)
9.34USDUpdated Sep 27, 2026
Total Debt (MRQ)
9.60MUSD
vs all stocks (USD)
Updated Sep 27, 2026
Total Debt to Equity (MRQ)
0.0096x
vs Diagnostics & Research peers
Updated Sep 27, 2026
Current Ratio (MRQ)
6.34x
vs Diagnostics & Research peers
Updated Sep 27, 2026
Book Value per Share (MRQ)
36.40USDUpdated Sep 27, 2026
Total Assets
1.21BUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
550.49MUSDFY2025 · Dec 31, 2025
Total Liabilities
106.81MUSDFY2025 · Dec 31, 2025
Total Non-current Assets
663.03MUSDFY2025 · Dec 31, 2025
Total Non-current Liabilities
21.84MUSDFY2025 · Dec 31, 2025
Total Current Liabilities
84.97MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents
50.19MUSDFY2025 · Dec 31, 2025
Other Short-term Investments
285.88MUSDFY2025 · Dec 31, 2025
Accounts Receivable
84.76MUSDFY2025 · Dec 31, 2025
Inventory
10.60MUSDFY2025 · Dec 31, 2025
Accounts Payable
18.65MUSDFY2025 · Dec 31, 2025
Short-term Debt
1.94MUSDFY2025 · Dec 31, 2025
Deferred Revenue
31.78MUSDFY2025 · Dec 31, 2025
Long-term Debt
5.74MUSDFY2025 · Dec 31, 2025
Other Non-current Liabilities
9.17MUSDFY2025 · Dec 31, 2025
Common Stock (Book)
3.00KUSDFY2025 · Dec 31, 2025
Retained Earnings
529.95MUSDFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.11BUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
13.46USDUpdated Sep 27, 2026
52-Week High
31.04USDUpdated Sep 27, 2026
52-Week Change
-0.45%
vs all stocks
Updated Sep 27, 2026
Beta
0.9280x
vs all stocks
Updated Sep 27, 2026
50-Day MA
19.81USDUpdated Sep 27, 2026
200-Day MA
20.14USDUpdated Sep 27, 2026
Avg 10-Day Volume
353.37KSharesUpdated Sep 27, 2026
Avg 30-Day Volume
299.18KSharesUpdated Sep 27, 2026
Diluted EPS (TTM)
-2.87USDUpdated Sep 27, 2026
Other Income / Expense
-9.77MUSDFY2025 · Dec 31, 2025
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How is this stock valued?
Inverted P/B With Liquidity And Equity Ratio
It trades below book value, with current assets ample and the balance sheet equity-funded.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -39.4%, lower than 95% of its Diagnostics & Research peers (median 8.5%)Significant